NewAmsterdam Pharma Company NV
$8.89
3
+$0+0% Friday 19:50
Statistics
Day High
-
Day Low
-
52W High
0
52W Low
0
Volume
1,580
Avg. Volume
0
Mkt Cap
0
P/E Ratio
0
Dividend Yield
-
Dividend
-
Earnings
6MayExpected
Expected EPS
-0.6147
Actual EPS
0
People Also Follow
This list is based on the watchlists of people on Stock Events who follow NAMSW. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap177.72B
Regeneron Pharmaceuticals
REGN
Mkt Cap114.81B
Novo Nordisk
NVO
Mkt Cap445.94B
Merck &
MRK
Mkt Cap318.55B
Pfizer
PFE
Mkt Cap169.83B
Astrazeneca
AZN
Mkt Cap244.04B
Sanofi
SNY
Mkt Cap128.21B
Lilly(Eli) &
LLY
Mkt Cap814.94B
Bristol-Myers Squibb
BMY
Mkt Cap86.44B
GSK
GSK
Mkt Cap81.55B
About
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Show more...
CEO
Employees
40
Country
NL
ISIN
NL00150012K9